Neurocrine Biosciences Highlights Significant Findings for INGREZZA
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has made strides in understanding the impact of INGREZZA® (valbenazine) capsules in reducing the disease burden in individuals with Huntington's disease. The results from the KINECT®-HD study have now been presented, showing significant patient-reported reductions in both cognitive and motor-related challenges when treated with INGREZZA compared to a placebo.
Study Insights from KINECT®-HD
The KINECT-HD study is a groundbreaking clinical trial that serves as the first of its kind to document measurable changes in several domains tied to the disease, addressing both motor and cognitive difficulties faced by patients. This study emphasizes the significant capability of INGREZZA in mitigating symptoms of chorea, a prominent and distressing symptom of Huntington's disease, while also tackling cognitive decline.
According to Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, “The KINECT-HD study proves INGREZZA’s ability to significantly reduce chorea and cognitive challenges, which often intertwine and complicate the lives of those affected by Huntington’s disease.” These findings are particularly noteworthy as they point to the potential for improved quality of life among those impacted by this progressive neurodegenerative disorder.
Research Findings and Analysis
During the 12-week Phase 3 clinical trial, the results indicated that participants receiving INGREZZA experienced a significant reduction in the severity of chorea, as measured by the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score. The post-hoc analyses assessed the impact of INGREZZA on the cognitive and motor burdens using the Huntington's Disease Health Index (HD-HI).
In these assessments, considerable improvements were noted across cognitive items, including memory loss and decision-making abilities. For instance, participants treated with INGREZZA noted improvements in memory loss, reporting a mean reduction of -0.9 on the HD-HI scale, contrasting with a -0.2 for those receiving placebo. This significant difference underscores the efficacy of INGREZZA in alleviating cognitive burdens associated with Huntington's disease.
Motor-Related Improvements
Motor-related items also saw a notable impact, with improvements in mobility and the ability to control involuntary movements. For participants taking INGREZZA, the reduction in mobility-related limitations was notably higher compared to the placebo group, showcasing the beneficial effects of valbenazine on the quality of movement and coordination. The significance of these findings cannot be overstated, as the ability to manage motor symptoms is crucial for maintaining independence in daily activities.
Upcoming Presentations and Further Studies
Neurocrine will share these findings at the upcoming Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress. The ongoing research reflects the company’s commitment to advancing treatments for neurological disorders. Additional studies will also focus on estimating the Minimal Clinically Important Difference (MCID) and examining how valbenazine assists in managing tardive dyskinesia and chorea associated with Huntington's disease.
About Huntington's Disease and INGREZZA
Huntington's disease is a hereditary neurodegenerative condition leading to progressive motor, cognitive, and psychiatric challenges. INGREZZA is the first approved therapy specifically targeting chorea related to this disease while also offering an effective treatment for tardive dyskinesia. Its unique mechanisms ensure that patients receive a therapeutic dose without the need for titration, providing immediate relief from debilitating symptoms.
Neurocrine Biosciences, with its focus on neuroscience, aims to address unmet medical needs in the treatment of disorders like Huntington's disease. The company has built a comprehensive portfolio that not only includes INGREZZA but also other innovative treatments aimed at improving patients' lives.
Frequently Asked Questions
What is the KINECT-HD study?
The KINECT-HD study is a clinical trial designed to evaluate the efficacy of INGREZZA as a treatment for chorea associated with Huntington's disease. It involved assessing patient-reported outcomes in cognitive and motor burdens.
How does INGREZZA work?
INGREZZA works by selectively inhibiting the release of dopamine in the brain, targeting the vesicular monoamine transporter 2 (VMAT2). This action helps to reduce uncontrolled movements associated with conditions like Huntington's disease and tardive dyskinesia.
What were the key findings from the study?
The study found that participants taking INGREZZA reported significant reductions in cognitive and motor-related symptoms compared to those on placebo, improving their overall quality of life.
Will the findings of this study be presented publicly?
Yes, the results are scheduled to be presented at the upcoming Advanced Therapeutics in Movement & Related Disorders Congress, an important venue for sharing groundbreaking research in this field.
What conditions does INGREZZA treat?
INGREZZA is approved for the treatment of tardive dyskinesia and chorea associated with Huntington's disease, aiming to improve motor control and reduce involuntary movements in patients.
